Brief: Ambrx Announces Arx517, A PSMA-Targeted Adc, Demonstrates A Promising 52% Psa50

Ambrx Biopharma

23/10/2023 13:22

Oct 23 (Reuters) - Ambrx Biopharma Inc  AMAM.O :
    * AMBRX ANNOUNCES ARX517, A PSMA-TARGETED ADC, DEMONSTRATES
A
PROMISING 52% PSA50 (≥50% REDUCTION) AND A HIGHLY DIFFERENTIATED
SAFETY AND PK PROFILE IN PATIENTS WITH MCRPC, WHO PROGRESSED ON
MULTIPLE FDA-APPROVED TREATMENTS

Source text for Eikon:  ID:nGNXbzQdDS 
Further company coverage:  AMAM.O 

 ((Reuters.Briefs@thomsonreuters.com;))